Special Issue

Oligonucleotide Aptamers for Diagnostics and Therapy

Message from the Guest Editors

In recent decades, oligonucleotide aptamers have emerged as versatile and powerful tools in biomedical research and clinical applications. These short, singlestranded nucleic acids can fold into unique threedimensional structures able to bind a plethora of different targets with high affinity and specificity. Compared to antibodies, aptamers offer several advantages, such as enhanced chemical stability, low immunogenicity, rapid and cost-effective synthesis, and ease of chemical modification. Aptamers are being increasingly explored for both diagnostic and therapeutic purposes, such as targeted drug delivery, and the development of new treatment strategies for complex diseases. This Special Issue aims to provide a comprehensive and multidisciplinary overview of the most recent advances in the field of aptamers, highlighting both opportunities and challenges in their application to diagnostics and therapy. We invite researchers to submit original papers, communications, and reviews regarding oligonucleotide aptamers for diagnostics and therapy to be considered for publication in this Special Issue of Pharmaceutics. We look forward to hearing from you.

Guest Editors

Dr. Claudia Riccardi

Department of Chemical Sciences, University of Naples Federico II, 80126 Naples, Italy

Dr. Ettore Napolitano

Department of Chemical Sciences, University of Naples Federico II, 80126 Naples, Italy

Deadline for manuscript submissions

31 March 2026



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/254182

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

